Published in J Virol on September 01, 2000
The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature (2003) 10.76
Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J Virol (2004) 5.35
The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J Virol (2003) 4.23
Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J Virol (2006) 2.63
Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G. J Virol (2004) 2.27
Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA. J Virol (2001) 2.16
Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells. J Virol (2006) 1.84
Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H. PLoS Pathog (2007) 1.70
The Vif and Vpr accessory proteins independently cause HIV-1-induced T cell cytopathicity and cell cycle arrest. Proc Natl Acad Sci U S A (2006) 1.58
Structural basis for hijacking CBF-β and CUL5 E3 ligase complex by HIV-1 Vif. Nature (2014) 1.52
Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding. J Virol (2007) 1.51
Human immunodeficiency virus type 1 Vif is efficiently packaged into virions during productive but not chronic infection. J Virol (2003) 1.49
Mutational analysis of the HIV-1 auxiliary protein Vif identifies independent domains important for the physical and functional interaction with HIV-1 reverse transcriptase. Nucleic Acids Res (2009) 1.48
Comprehensive investigation of the molecular defect in vif-deficient human immunodeficiency virus type 1 virions. J Virol (2003) 1.41
Role of Vif in stability of the human immunodeficiency virus type 1 core. J Virol (2000) 1.34
The multimerization of human immunodeficiency virus type I Vif protein: a requirement for Vif function in the viral life cycle. J Biol Chem (2000) 1.32
HIV-1 RNA dimerization: It takes two to tango. AIDS Rev (2009) 1.29
Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. J Biol Chem (2002) 1.17
The dimerization domain of HIV-1 viral infectivity factor Vif is required to block virion incorporation of APOBEC3G. Retrovirology (2007) 1.14
Characterization of the interaction of full-length HIV-1 Vif protein with its key regulator CBFβ and CRL5 E3 ubiquitin ligase components. PLoS One (2012) 1.12
Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors. Microbiol Mol Biol Rev (2009) 1.12
The HIV-1 Vif PPLP motif is necessary for human APOBEC3G binding and degradation. Virology (2008) 1.11
Features, processing states, and heterologous protein interactions in the modulation of the retroviral nucleocapsid protein function. RNA Biol (2010) 1.08
Vif is a RNA chaperone that could temporally regulate RNA dimerization and the early steps of HIV-1 reverse transcription. Nucleic Acids Res (2007) 1.07
Human immunodeficiency virus type 1 (HIV-1) induces the cytoplasmic retention of heterogeneous nuclear ribonucleoprotein A1 by disrupting nuclear import: implications for HIV-1 gene expression. J Biol Chem (2009) 1.06
Mass spectrometry analysis of HIV-1 Vif reveals an increase in ordered structure upon oligomerization in regions necessary for viral infectivity. Proteins (2007) 1.04
Implication of the lymphocyte-specific nuclear body protein Sp140 in an innate response to human immunodeficiency virus type 1. J Virol (2002) 1.03
HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors. Mol Aspects Med (2010) 1.03
Advances in the structural understanding of Vif proteins. Curr HIV Res (2008) 1.03
Properties and functions of the nucleocapsid protein in virus assembly. RNA Biol (2010) 1.02
HIV-1 Vif binds to APOBEC3G mRNA and inhibits its translation. Nucleic Acids Res (2009) 1.00
Role of HIV-1 RNA and protein determinants for the selective packaging of spliced and unspliced viral RNA and host U6 and 7SL RNA in virus particles. Nucleic Acids Res (2011) 0.97
The Vif accessory protein alters the cell cycle of human immunodeficiency virus type 1 infected cells. Virology (2006) 0.92
Intravirion processing of the human immunodeficiency virus type 1 Vif protein by the viral protease may be correlated with Vif function. J Virol (2002) 0.91
On the solution conformation and dynamics of the HIV-1 viral infectivity factor. J Mol Biol (2011) 0.91
Importance of the proline-rich multimerization domain on the oligomerization and nucleic acid binding properties of HIV-1 Vif. Nucleic Acids Res (2010) 0.90
Inhibitors of human immunodeficiency virus type 1 reverse transcriptase target distinct phases of early reverse transcription. J Virol (2001) 0.89
Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS. Future Virol (2009) 0.89
Ring finger protein ZIN interacts with human immunodeficiency virus type 1 Vif. J Virol (2004) 0.86
Vif is an auxiliary factor of the HIV-1 reverse transcriptase and facilitates abasic site bypass. Biochem J (2004) 0.86
Human immunodeficiency virus type-1 reverse transcriptase exists as post-translationally modified forms in virions and cells. Retrovirology (2008) 0.84
Vif is largely absent from human immunodeficiency virus type 1 mature virions and associates mainly with viral particles containing unprocessed gag. J Virol (2001) 0.83
HIV-1 Vif N-terminal motif is required for recruitment of Cul5 to suppress APOBEC3. Retrovirology (2014) 0.83
APOBEC3G impairs the multimerization of the HIV-1 Vif protein in living cells. J Virol (2013) 0.81
Positive selection on HIV accessory proteins and the analysis of molecular adaptation after interspecies transmission. J Mol Evol (2008) 0.80
Recent Insights into HIV Accessory Proteins. Curr Infect Dis Rep (2003) 0.78
Characterization of RNA binding and chaperoning activities of HIV-1 Vif protein. Importance of the C-terminal unstructured tail. RNA Biol (2014) 0.78
Inhibition of endogenous reverse transcription of human and nonhuman primate lentiviruses: potential for development of lentivirucides. Virology (2006) 0.78
Structural analysis of viral infectivity factor of HIV type 1 and its interaction with A3G, EloC and EloB. PLoS One (2014) 0.76
Requirements for nucleocapsid-mediated regulation of reverse transcription during the late steps of HIV-1 assembly. Sci Rep (2016) 0.76
Constructing an integrated genetic and epigenetic cellular network for whole cellular mechanism using high-throughput next-generation sequencing data. BMC Syst Biol (2016) 0.75
Identification of Vimentin as a Potential Therapeutic Target against HIV Infection. Viruses (2016) 0.75
Coevolutionary analyses require phylogenetically deep alignments and better null models to accurately detect inter-protein contacts within and between species. BMC Bioinformatics (2015) 0.75
Genetic and functional characterization of HIV-1 Vif on APOBEC3G degradation: First report of emergence of B/C recombinants from North India. Sci Rep (2015) 0.75
Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science (1990) 35.96
Conserved structures and diversity of functions of RNA-binding proteins. Science (1994) 14.75
hnRNP proteins and the biogenesis of mRNA. Annu Rev Biochem (1993) 11.44
A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell (1998) 10.14
The HIV 'A' (sor) gene product is essential for virus infectivity. Nature (1987) 7.51
Interrelationships of the pathways of mRNA decay and translation in eukaryotic cells. Annu Rev Biochem (1996) 7.08
Tables for estimating sedimentation through linear concentration gradients of sucrose solution. Anal Biochem (1967) 6.48
RNA binding specificity of hnRNP A1: significance of hnRNP A1 high-affinity binding sites in pre-mRNA splicing. EMBO J (1994) 6.17
The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science (1987) 6.16
Identification of a sequence required for efficient packaging of human immunodeficiency virus type 1 RNA into virions. J Virol (1989) 6.11
Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol (1993) 6.11
Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol (1992) 5.85
RNA chaperones and the RNA folding problem. J Biol Chem (1995) 5.67
RNA packaging. Curr Top Microbiol Immunol (1996) 4.88
Classification and purification of proteins of heterogeneous nuclear ribonucleoprotein particles by RNA-binding specificities. Mol Cell Biol (1988) 4.73
Structure and function of nuclear and cytoplasmic ribonucleoprotein particles. Annu Rev Cell Biol (1986) 4.33
Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat Med (1998) 3.84
First glimpses at structure-function relationships of the nucleocapsid protein of retroviruses. J Mol Biol (1995) 3.63
RNA secondary structure and binding sites for gag gene products in the 5' packaging signal of human immunodeficiency virus type 1. J Virol (1995) 3.53
A study of the dimer formation of Rous sarcoma virus RNA and of its effect on viral protein synthesis in vitro. Nucleic Acids Res (1990) 3.50
A mutant of human immunodeficiency virus with reduced RNA packaging and abnormal particle morphology. J Virol (1990) 3.33
The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes. J Virol (1996) 3.22
Specific binding of human immunodeficiency virus type 1 gag polyprotein and nucleocapsid protein to viral RNAs detected by RNA mobility shift assays. J Virol (1993) 3.15
Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1. J Virol (1993) 3.12
Identification of highly attenuated mutants of simian immunodeficiency virus. J Virol (1998) 2.94
Specific binding of HIV-1 nucleocapsid protein to PSI RNA in vitro requires N-terminal zinc finger and flanking basic amino acid residues. EMBO J (1994) 2.86
HIV accessory proteins: leading roles for the supporting cast. Cell (1995) 2.82
An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. J Virol (1998) 2.73
Construction and in vitro properties of HIV-1 mutants with deletions in "nonessential" genes. AIDS Res Hum Retroviruses (1994) 2.72
Endogenous reverse transcription of human immunodeficiency virus type 1 in physiological microenviroments: an important stage for viral infection of nondividing cells. J Virol (1996) 2.70
Highly purified human immunodeficiency virus type 1 reveals a virtual absence of Vif in virions. J Virol (1999) 2.66
Purification and visualization of native spliceosomes. Cell (1988) 2.57
Human immunodeficiency virus type 1 Vif- mutant particles from restrictive cells: role of Vif in correct particle assembly and infectivity. J Virol (1995) 2.45
The Vif and Gag proteins of human immunodeficiency virus type 1 colocalize in infected human T cells. J Virol (1997) 2.39
Subcellular localization of the Vif protein of human immunodeficiency virus type 1. J Virol (1994) 2.35
Complementation of vif-defective human immunodeficiency virus type 1 by primate, but not nonprimate, lentivirus vif genes. J Virol (1995) 2.35
Role of Vif in human immunodeficiency virus type 1 reverse transcription. J Virol (1996) 2.35
The human poly(A)-binding protein 1 shuttles between the nucleus and the cytoplasm. J Biol Chem (1998) 2.23
Peripheral blood mononuclear cells produce normal amounts of defective Vif- human immunodeficiency virus type 1 particles which are restricted for the preretrotranscription steps. J Virol (1995) 2.19
Sequence-specific binding of human immunodeficiency virus type 1 nucleocapsid protein to short oligonucleotides. J Virol (1998) 2.14
Role of vif during packing of the core of HIV-1. Virology (1994) 2.01
Binding sites of viral protein P19 onto Rous sarcoma virus RNA and possible controls of viral functions. J Mol Biol (1982) 2.00
Reverse transcription takes place within extracellular HIV-1 virions: potential biological significance. AIDS Res Hum Retroviruses (1993) 1.88
Replication and pathogenicity of human immunodeficiency virus type 1 accessory gene mutants in SCID-hu mice. J Virol (1996) 1.80
Human immunodeficiency virus type 1 Vif does not influence expression or virion incorporation of gag-, pol-, and env-encoded proteins. J Virol (1996) 1.76
Transcomplementation of VIF- HIV-1 mutants in CEM cells suggests that VIF affects late steps of the viral life cycle. Virology (1993) 1.74
Characterization of human immunodeficiency virus type 1 Vif particle incorporation. J Virol (1996) 1.69
The major protein of messenger ribonucleoprotein particles in somatic cells is a member of the Y-box binding transcription factor family. J Biol Chem (1995) 1.65
Partial rescue of the Vif-negative phenotype of mutant human immunodeficiency virus type 1 strains from nonpermissive cells by intravirion reverse transcription. J Virol (2000) 1.60
Essential role of vif in establishing productive HIV-1 infection in peripheral blood T lymphocytes and monocyte/macrophages. J Acquir Immune Defic Syndr (1994) 1.58
Human immunodeficiency virus type 1 Vif protein binds to the Pr55Gag precursor. J Virol (1997) 1.55
The double-stranded RNA-binding protein Staufen is incorporated in human immunodeficiency virus type 1: evidence for a role in genomic RNA encapsidation. J Virol (2000) 1.50
Vif and the p55(Gag) polyprotein of human immunodeficiency virus type 1 are present in colocalizing membrane-free cytoplasmic complexes. J Virol (1999) 1.44
Phenotypically Vif- human immunodeficiency virus type 1 is produced by chronically infected restrictive cells. J Virol (1997) 1.38
The major core protein of messenger ribonucleoprotein particles (p50) promotes initiation of protein biosynthesis in vitro. J Biol Chem (1998) 1.34
Translational repression dependent on the interaction of the Xenopus Y-box protein FRGY2 with mRNA. Role of the cold shock domain, tail domain, and selective RNA sequence recognition. J Biol Chem (1996) 1.30
In vivo genetic variability of the HIV-1 vif gene. Virology (1994) 1.18
Amphipathic domains in the C terminus of the transmembrane protein (gp41) permeabilize HIV-1 virions: a molecular mechanism underlying natural endogenous reverse transcription. Proc Natl Acad Sci U S A (1996) 1.15
Interaction and co-encapsidation of human immunodeficiency virus type 1 Gag and Vif recombinant proteins. J Gen Virol (1998) 1.12
Comparative analyses of human immunodeficiency virus type 1 (HIV-1) and HIV-2 Vif mutants. J Virol (1995) 1.11
Interaction of mRNA with proteins in vesicular stomatitis virus-infected cells. J Virol (1986) 1.09
Conservation of an intact human immunodeficiency virus type 1 vif gene in vitro and in vivo. J Virol (1995) 1.06
Virion incorporation of human immunodeficiency virus type-1 Vif is determined by intracellular expression level and may not be necessary for function. Virology (1998) 1.01
Diversity of the vif gene of human immunodeficiency virus type 1 in Uganda. J Gen Virol (1997) 0.99
A quantitative reverse transcriptase-polymerase chain reaction for HIV-1-specific RNA species. J Virol Methods (1992) 0.94
Inhibition of protein synthesis in vesicular stomatitis virus infected Chinese hamster ovary cells: role of virus mRNA-ribonucleoprotein particle. Biochemistry (1984) 0.80
The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell (1996) 17.13
A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science (1998) 8.36
Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med (1998) 7.48
Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J Virol (1995) 5.01
Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA (1999) 4.98
A critical role for DNA end-joining proteins in both lymphogenesis and neurogenesis. Cell (1998) 4.78
Regulation of gliogenesis in the central nervous system by the JAK-STAT signaling pathway. Science (1997) 4.26
Structure of a glutamate-receptor ligand-binding core in complex with kainate. Nature (1998) 4.14
RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A (2000) 3.95
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol (2001) 3.92
Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol (1994) 3.79
Detection of human immunodeficiency virus type 1 provirus in mononuclear cells by in situ polymerase chain reaction. N Engl J Med (1992) 3.64
CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization. J Virol (1998) 3.60
A multivalent PDZ-domain protein assembles signalling complexes in a G-protein-coupled cascade. Nature (1997) 3.54
Pathogenesis of infection with human immunodeficiency virus. N Engl J Med (1987) 3.45
Defects in regulation of apoptosis in caspase-2-deficient mice. Genes Dev (1998) 3.24
Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med (1998) 3.14
Transforming growth factor beta-induced phosphorylation of Smad3 is required for growth inhibition and transcriptional induction in epithelial cells. Proc Natl Acad Sci U S A (1997) 2.97
Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux. J Biol Chem (1997) 2.95
Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood (2001) 2.88
Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology (2009) 2.76
Two orphan seven-transmembrane segment receptors which are expressed in CD4-positive cells support simian immunodeficiency virus infection. J Exp Med (1997) 2.75
DNA hypomethylation perturbs the function and survival of CNS neurons in postnatal animals. J Neurosci (2001) 2.75
High STOP-Bang score indicates a high probability of obstructive sleep apnoea. Br J Anaesth (2012) 2.71
Endogenous reverse transcription of human immunodeficiency virus type 1 in physiological microenviroments: an important stage for viral infection of nondividing cells. J Virol (1996) 2.70
Caspase inhibitor affords neuroprotection with delayed administration in a rat model of neonatal hypoxic-ischemic brain injury. J Clin Invest (1998) 2.64
HIV-1 entry and macrophage inflammatory protein-1beta-mediated signaling are independent functions of the chemokine receptor CCR5. J Biol Chem (1997) 2.55
Regulation of the proinflammatory effects of Fas ligand (CD95L). Science (1998) 2.43
Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. Proc Natl Acad Sci U S A (1996) 2.32
Retracted Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single-chain antibody. Proc Natl Acad Sci U S A (1994) 2.30
Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies. J Virol (1998) 2.28
A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5. J Virol (1998) 2.28
Expression and activation of 15-lipoxygenase pathway in severe asthma: relationship to eosinophilic phenotype and collagen deposition. Clin Exp Allergy (2002) 2.26
Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. Neuron (1999) 2.25
Role of the proneural gene, atonal, in formation of Drosophila chordotonal organs and photoreceptors. Development (1995) 2.25
Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. J Clin Invest (1999) 2.21
Decreased interferon-alpha production in HIV-infected patients correlates with numerical and functional deficiencies in circulating type 2 dendritic cell precursors. Clin Immunol (2001) 2.19
Structure and genomic organization of the human AUF1 gene: alternative pre-mRNA splicing generates four protein isoforms. Genomics (1998) 2.17
Over-expression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice. Hum Mol Genet (2001) 2.13
Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms. J Mol Cell Cardiol (1994) 2.12
Superparamagnetic gadonanotubes are high-performance MRI contrast agents. Chem Commun (Camb) (2005) 2.05
Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med (2000) 2.04
A hierarchical approach to color image segmentation using homogeneity. IEEE Trans Image Process (2000) 1.99
Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol (2008) 1.92
KCNE1 mutations cause jervell and Lange-Nielsen syndrome. Nat Genet (1997) 1.90
Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4. Proc Natl Acad Sci U S A (1997) 1.89
Molecular cloning of human paxillin, a focal adhesion protein phosphorylated by P210BCR/ABL. J Biol Chem (1995) 1.86
Human herpesvirus type 8 DNA sequences in cell-free plasma and mononuclear cells of Kaposi's sarcoma patients. J Infect Dis (1996) 1.85
Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Cancer Res (2001) 1.80
Generation of mammalian cells stably expressing multiple genes at predetermined levels. Anal Biochem (2000) 1.79
Nephrin is involved in podocyte maturation but not survival during glomerular development. Kidney Int (2007) 1.79
Blocked early-stage latency in the peripheral blood cells of certain individuals infected with human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1992) 1.76
Pneumococcal capsular polysaccharide preparations may contain non-C-polysaccharide contaminants that are immunogenic. Clin Diagn Lab Immunol (1999) 1.74
Transcriptional activation of the human glutathione peroxidase promoter by p53. J Biol Chem (1999) 1.73
Transduction of hepatocellular carcinoma (HCC) using recombinant adeno-associated virus (rAAV): in vitro and in vivo effects of genotoxic agents. J Hepatol (2000) 1.73
Ski/Sno and TGF-beta signaling. Cytokine Growth Factor Rev (2001) 1.71
Analysis of plasma and urinary tea polyphenols in human subjects. Cancer Epidemiol Biomarkers Prev (1995) 1.70
Preferential ATP-binding cassette transporter A1-mediated cholesterol efflux from late endosomes/lysosomes. J Biol Chem (2001) 1.68
The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells. J Biol Chem (1999) 1.68
Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation (1998) 1.68
Characterization of the ileal microbiota in rejecting and nonrejecting recipients of small bowel transplants. Am J Transplant (2011) 1.67
beta-arrestin differentially regulates the chemokine receptor CXCR4-mediated signaling and receptor internalization, and this implicates multiple interaction sites between beta-arrestin and CXCR4. J Biol Chem (2000) 1.67
Calmodulin regulation of Drosophila light-activated channels and receptor function mediates termination of the light response in vivo. Cell (1997) 1.64
The orphan seven-transmembrane receptor apj supports the entry of primary T-cell-line-tropic and dualtropic human immunodeficiency virus type 1. J Virol (1998) 1.63
Different human TFIIIB activities direct RNA polymerase III transcription from TATA-containing and TATA-less promoters. Genes Dev (2000) 1.61
Partial rescue of the Vif-negative phenotype of mutant human immunodeficiency virus type 1 strains from nonpermissive cells by intravirion reverse transcription. J Virol (2000) 1.60
High-throughput microRNAome analysis in human germ cell tumours. J Pathol (2007) 1.60
CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev (1998) 1.59
Gq alpha protein function in vivo: genetic dissection of its role in photoreceptor cell physiology. Neuron (1995) 1.58
Stabilization of human immunodeficiency virus type 1 envelope glycoprotein trimers by disulfide bonds introduced into the gp41 glycoprotein ectodomain. J Virol (1998) 1.58
atonal regulates neurite arborization but does not act as a proneural gene in the Drosophila brain. Neuron (2000) 1.58
Recombinant rabies virus as potential live-viral vaccines for HIV-1. Proc Natl Acad Sci U S A (2000) 1.57
Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. Mol Cell Biol (1997) 1.57
Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo. J Virol (2000) 1.55
p38 kinase mediates UV-induced phosphorylation of p53 protein at serine 389. J Biol Chem (1999) 1.55
PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway. Proc Natl Acad Sci U S A (2000) 1.55
Post-translational modifications of water-soluble human lens crystallins from young adults. J Biol Chem (1994) 1.53
Intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle by targeting human immunodeficiency virus type 1 integrase. J Virol (1996) 1.50
Characterization of simian-human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeys. J Virol (1998) 1.49
Sequence analysis and expression of a cDNA clone encoding a 98-kDa allergen in Dermatophagoides farinae. Clin Exp Allergy (1999) 1.48
Nuclear isomers in superheavy elements as stepping stones towards the island of stability. Nature (2006) 1.48
SCF E3 ubiquitin ligases as anticancer targets. Curr Cancer Drug Targets (2011) 1.46
Pb(II)-translocating P-type ATPases. J Biol Chem (1998) 1.46
p130/pRb2 has growth suppressive properties similar to yet distinctive from those of retinoblastoma family members pRb and p107. Cancer Res (1994) 1.46
Electric-field control of nonvolatile magnetization in Co40Fe40B20/Pb(Mg(1/3)Nb(2/3))(0.7)Ti(0.3)O3 structure at room temperature. Phys Rev Lett (2012) 1.44
Prostaglandin endoperoxide H synthase-1: the functions of cyclooxygenase active site residues in the binding, positioning, and oxygenation of arachidonic acid. J Biol Chem (2000) 1.43
Detection of HIV-1 proviral DNA in sperm from HIV-1-infected men. AIDS (1994) 1.43
Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology (2007) 1.43
Differential effects of cAMP in neurons and astrocytes. Role of B-raf. J Biol Chem (1999) 1.43
TIMP-3 induces cell death by stabilizing TNF-alpha receptors on the surface of human colon carcinoma cells. Cytokine (1997) 1.42
Great vessel management for endovascular exclusion of aortic arch aneurysms and dissections. Eur J Vasc Endovasc Surg (2006) 1.41
New perspectives on the biology of acute GVHD. Bone Marrow Transplant (2009) 1.40
4-Thiazolidinones: novel inhibitors of the bacterial enzyme MurB. Bioorg Med Chem Lett (2000) 1.38
Structural and functional characterization of human CXCR4 as a chemokine receptor and HIV-1 co-receptor by mutagenesis and molecular modeling studies. J Biol Chem (2001) 1.38